TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9540015

Group type: EXPERIMENTAL
Intervention: Diet intervention (decreasing calories and fat intake)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Exercise intervention (goal of 1,500 kcal/week of moderate activity)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Combination of diet plus exercise
Number of subjects: 154

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: All treatment groups (diet, exercise, combination)
Number of subjects: 154
Study: 8210250

Group type: EXPERIMENTAL
Intervention: MST-16 at 1,600 mg/body for 5 consecutive days repeating every 4 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MST-16 at 1,200 mg/body for 10-14 consecutive days every 5 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MST-16 at 1,200 mg/body daily for at least 4 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MST-16 (all doses)
Number of subjects: 28
Study: 2508457

Group type: EXPERIMENTAL
Intervention: Intravenous nicardipine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous nitroglycerin
Number of subjects: 20
Study: 22216522

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg and 200 mg daily)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Practolol (200 mg and 400 mg daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31511289

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasonography (CEUS)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Three-dimensional power Doppler (3DPD) angiography
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CEUS and 3DPD
Number of subjects: 42
Study: 29061169

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) for 30 minutes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo stimulation for 30 minutes
Number of subjects: 40
Study: 25398967

Group type: EXPERIMENTAL
Intervention: Calcium plus Vitamin D3 (1000 mg/d of calcium plus 400 IU/d of vitamin D3)
Number of subjects: 35983

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35983
Study: 23514701

Group type: EXPERIMENTAL
Intervention: TMP transdermal patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: TMP oral tablets (TMPP)
Number of subjects: 0
Study: 21555034

Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 20137710

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no atorvastatin)
Number of subjects: 140
Study: 16924336

Group type: EXPERIMENTAL
Intervention: Passive topical application of Carisolv + SRP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Active topical application of Carisolv + SRP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multiple applications of Carisolv + SRP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SRP + 24% EDTA
Number of subjects: 60

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical application of Carisolv + SRP + 24% EDTA
Number of subjects: 60
Study: 14714579

Group type: EXPERIMENTAL
Intervention: Imidapril (5‐10 mg/day) or benazepril (10‐20 mg/day) for 6 weeks
Number of subjects: 517
Study: 10986059

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy including multiple, prolonged courses of corticosteroid (dexamethasone)
Number of subjects: 1409

Group type: EXPERIMENTAL
Intervention: Two 21-day dexamethasone courses
Number of subjects: 1409

Group type: EXPERIMENTAL
Intervention: Age group 10 to 20 years old
Number of subjects: 1409

Group type: EXPERIMENTAL
Intervention: Ethnic groups
Number of subjects: 1409

Group type: EXPERIMENTAL
Intervention: Overall ON diagnosis
Number of subjects: 1409

Group type: EXPERIMENTAL
Intervention: Orthopedic procedures
Number of subjects: 1409

Group type: COMPARATOR
Intervention: Event-free survival
Number of subjects: 1409
Study: 9568323

Group type: EXPERIMENTAL
Intervention: Serum IL-8 levels in burned patients postburn
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Serum IL-8 levels in septic patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Serum IL-8 levels in healthy laboratory personnel
Number of subjects: 10
Study: 8396025

Group type: EXPERIMENTAL
Intervention: Quorn myco‐protein (high fibre)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chicken (low-fibre)
Number of subjects: 18
Study: 3534246

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment over 12 weeks (6-week standard trial followed by 6-week continuation for responders)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31547949

Group type: EXPERIMENTAL
Intervention: Splint therapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Splint therapy with ultrasound‐guided arthrocentesis
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Splint therapy with low‐level laser therapy
Number of subjects: 45
Study: 29921302

Group type: EXPERIMENTAL
Intervention: Active participation in antenatal care plus current routine care
Number of subjects: 14

Group type: COMPARATOR
Intervention: Current routine care
Number of subjects: 14
Study: 26600285

Group type: EXPERIMENTAL
Intervention: AHH intervention (community-based bilingual promotoras providing in-person or telephone patient engagement)
Number of subjects: 348

Group type: COMPARATOR
Intervention: DHS PCMH team usual care (PCMHUC)
Number of subjects: 348
Study: 23943291

Group type: EXPERIMENTAL
Intervention: Q1 (TTO instruction not emphasizing reduced life expectancy)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Q2 (TTO instruction emphasizing reduced life expectancy)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Q1
Number of subjects: 656

Group type: COMPARATOR
Intervention: Q2
Number of subjects: 656
Study: 22588407

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia and femoral nerve block (PCEA/FNB)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Periarticular injection (PAI)
Number of subjects: 90
Study: 20565314

Group type: EXPERIMENTAL
Intervention: Unit-dose pipettes
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional eye drop bottles
Number of subjects: 41
Study: 18391094

Group type: EXPERIMENTAL
Intervention: Stepped care treatment with chlorthalidone and atenolol (n=2365)
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Placebo (n=2371)
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation group
Number of subjects: 4736
Study: 15925877

Group type: EXPERIMENTAL
Intervention: Intra-arterial urokinase
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 12866040

Group type: EXPERIMENTAL
Intervention: Aspirin exclusively
Number of subjects: 27290

Group type: EXPERIMENTAL
Intervention: Non-aspirin NSAIDs exclusively (e.g., ibuprofen)
Number of subjects: 27290

Group type: EXPERIMENTAL
Intervention: Both aspirin and non-aspirin NSAIDs
Number of subjects: 27290

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis diagnosis
Number of subjects: 27290

Group type: EXPERIMENTAL
Intervention: Osteoarthritis diagnosis
Number of subjects: 27290

Group type: COMPARATOR
Intervention: No use of aspirin or other non-aspirin NSAIDs
Number of subjects: 27290
Study: 10819336

Group type: EXPERIMENTAL
Intervention: Zanamivir (10 mg, inhaled, twice daily for 5 days)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 471
Study: 8887036

Group type: EXPERIMENTAL
Intervention: Glycyrrhizin (GL) given intravenously at a dose of 40 ml (0.2% solution) daily for 4 consecutive weeks.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group received only dental cleaning.
Number of subjects: 17
Study: 2058066

Group type: EXPERIMENTAL
Intervention: KLH
Number of subjects: 42

Group type: COMPARATOR
Intervention: BCG
Number of subjects: 42
Study: 6644525

Group type: EXPERIMENTAL
Intervention: Faschingbauer Abbreviated MMPI (FAM)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: MMPI‐168
Number of subjects: 514

Group type: COMPARATOR
Intervention: Full Minnesota Multiphasic Personality Inventory (MMPI)
Number of subjects: 514
Study: 30795736

Group type: EXPERIMENTAL
Intervention: Chinese version of Attitudes towards guidelines scale
Number of subjects: 768
Study: 29061547

Group type: EXPERIMENTAL
Intervention: Tiger‐II catheter
Number of subjects: 320

Group type: COMPARATOR
Intervention: Judkins catheter
Number of subjects: 320
Study: 27880804

Group type: EXPERIMENTAL
Intervention: Multi-disciplinary intervention in a community-based obesity programme
Number of subjects: 239
Study: 24858506

Group type: EXPERIMENTAL
Intervention: Forest therapy (viewing a real forest landscape for 15 min)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Urban area viewing (control group, viewing urban area for 15 min)
Number of subjects: 98
Study: 22578980

Group type: EXPERIMENTAL
Intervention: Mate tea (MT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Dietary intervention (DI)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Mate tea with dietary intervention (MD)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (DI and MD)
Number of subjects: 74
Study: 19853510

Group type: COMPARATOR
Intervention: Lenalidomide 25 mg on days 1-21 plus dexamethasone 40 mg on days 1-4, 9-12, and 17-20 of a 28-day cycle (high dose)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg on days 1-21 plus dexamethasone 40 mg on days 1, 8, 15, and 22 of a 28-day cycle (low dose)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone group
Number of subjects: 445

Group type: COMPARATOR
Intervention: High-dose dexamethasone group
Number of subjects: 445

Group type: COMPARATOR
Intervention: High-dose regimen
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Low-dose regimen
Number of subjects: 445
Study: 17699177

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillators
Number of subjects: 0
Study: 16197655

Group type: EXPERIMENTAL
Intervention: Milnacipran (50 mg/day increasing to 100 mg/day after 1 week)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 70
Study: 14499730

Group type: EXPERIMENTAL
Intervention: Aspirin and heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study: 10440426

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8707167

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg)
Number of subjects: 959

Group type: COMPARATOR
Intervention: Standard unfractionated heparin (Ca-heparin, 3 x 5,000 U)
Number of subjects: 959
Study: 1867903

Group type: EXPERIMENTAL
Intervention: Contract condition with co-worker-delivered reminders, prompting at least once a month for six months, plus mailed prompts monthly.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control condition with mailed prompts monthly.
Number of subjects: 36
Study: 6284597

Group type: EXPERIMENTAL
Intervention: Rivanol (6,9‐diamino‐2‐oxyethyl acridine lactate) during elective midtrimester abortions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivanol (6,9‐diamino‐2‐oxyethyl acridine lactate) in women with fetal death
Number of subjects: 0
Study: 31151456

Group type: EXPERIMENTAL
Intervention: CBL-based CAFA
Number of subjects: 389

Group type: COMPARATOR
Intervention: Control group (non-CBL CAFA)
Number of subjects: 389
Study: 28703621

Group type: EXPERIMENTAL
Intervention: Cued budget categories (attention directed to one side of the screen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cued attention (manipulated through spatial cuing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual attention and mental attention (orthogonally manipulated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cued categories (attention increased prioritization)
Number of subjects: 0
Study: 25647757

Group type: EXPERIMENTAL
Intervention: R-L+ stimulation (anodal stimulation of left PPC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: R+L- stimulation (anodal stimulation of right PPC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study: 25443069

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 144
Study: 22582197

Group type: EXPERIMENTAL
Intervention: Euhydrated condition
Number of subjects: 19

Group type: COMPARATOR
Intervention: Hypohydrated condition
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 19
Study: 19683119

Group type: EXPERIMENTAL
Intervention: Rusch ViewMax
Number of subjects: 26

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 26
Study: 17577847

Group type: EXPERIMENTAL
Intervention: Direct Stenting (DS)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional Stenting (CS)
Number of subjects: 300
Study: 10990103

Group type: EXPERIMENTAL
Intervention: Enteral plus parenteral nutrition (treatment group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Enteral nutrition plus placebo (placebo group)
Number of subjects: 120
Study: 8741021

Group type: EXPERIMENTAL
Intervention: EGb 761 (240 mg daily)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 1331493

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 200 mg kg‐1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 300 mg kg‐1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 400 mg kg‐1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 500 mg kg‐1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 100 mg kg‐1
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (CaCO3 500 mg kg‐1)
Number of subjects: 9
Study: 4019271

Group type: EXPERIMENTAL
Intervention: Delayed 252Cf implant therapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Early 252Cf implant therapy
Number of subjects: 82
Study: 31115845

Group type: EXPERIMENTAL
Intervention: Participants in the SELECT BC trial receiving either S-1 or taxane as first-line treatment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-participants who declined to participate in the SELECT BC trial.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-participants who received the same chemotherapy (S-1 or taxane) after declining participation.
Number of subjects: 0
Study: 30439808

Group type: EXPERIMENTAL
Intervention: Watery eye
Number of subjects: 210

Group type: COMPARATOR
Intervention: Cataract eye
Number of subjects: 210

Group type: COMPARATOR
Intervention: Macular region pathology
Number of subjects: 210
Study: 26636418

Group type: EXPERIMENTAL
Intervention: P‐3074 1 mL (2.275 mg) applied to the scalp once a day (o.d.)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: P‐3074 1 mL (2.275 mg) applied to the scalp twice a day (b.i.d.)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1 mg oral tablet of finasteride once a day (o.d.)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: P‐3074 100 μL applied o.d.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: P‐3074 200 μL applied o.d.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: P‐3074 300 μL applied o.d.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: P‐3074 400 μL applied o.d.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vehicle applied o.d.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 50
Study: 24484178

Group type: EXPERIMENTAL
Intervention: rF-B7.1 or rF-TRICOM (3.7×10(7) or 3.7×10(8) plaque-forming units) administered by intralesional injection every 4 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rF-B7.1 or rF-TRICOM
Number of subjects: 12
Study: 23100396

Group type: EXPERIMENTAL
Intervention: Evaluation of 1, 1-2, 1-3, ..., 1-10 serial skip sections of 3-mm punch biopsies
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Estimating 95% confidence intervals (CIs) of ENFs/mm
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: New continuous measure combining nerve conduction and ENFs/mm
Number of subjects: 90
Study: 19857185

Group type: COMPARATOR
Intervention: Therapeutic cancer vaccines (various types including antigen-presenting-cell-based, vector-based, and whole tumor cell vaccines)
Number of subjects: 0
Study: 18834274

Group type: EXPERIMENTAL
Intervention: Ethnic/racial minority patients (American Indian, African American, Hispanic, Asian)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Whites
Number of subjects: 269
Study: 16094110

Group type: EXPERIMENTAL
Intervention: Topical lysine-aspirin (16 mg every 48 hours for 6 months)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 12173902

Group type: EXPERIMENTAL
Intervention: Primary infarct intervention in octogenarians (1997-1998)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Younger patients (<80 years) treated with primary infarct intervention (1997-1998)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Octogenarians treated in 1991-1994
Number of subjects: 40
Study: 10599182

Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7564036

Group type: EXPERIMENTAL
Intervention: Warfarin (anticoagulant) alone for 21 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ticlopidine (200 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined use of anticoagulants and antiplatelet agents
Number of subjects: 24
Study: 1793024

Group type: EXPERIMENTAL
Intervention: Gold treatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both gold and MTX treatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Improved group (overall)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Unimproved group (overall)
Number of subjects: 44
Study: 31782786

Group type: EXPERIMENTAL
Intervention: Combination of glucocorticoids (GCs) and cyclophosphamide (CYC)
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GCs) only
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Age ≥65 years
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Pulmonary involvement
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Five Factor Score ≥1
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Occurrence of severe infections (SI)
Number of subjects: 733
Study: 31474526

Group type: EXPERIMENTAL
Intervention: Health care practitioner counseling on medication disposal
Number of subjects: 400

Group type: COMPARATOR
Intervention: No counseling (control group)
Number of subjects: 400
Study: 28209450

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25933204

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over dominant M1 at least 40 mins before task performance (Experiment 1)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Anodal tDCS directly before task performance (Experiment 2)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Anodal tDCS during task performance (Experiment 3)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 52
Study: 22926533

Group type: EXPERIMENTAL
Intervention: Oxygen pressure injection (OPI) device during MAL‐PDT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard MAL‐PDT without OPI
Number of subjects: 0
Study: 21317618

Group type: EXPERIMENTAL
Intervention: E-OA-07
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20234119

Group type: EXPERIMENTAL
Intervention: Culturally tailored genetic counseling (CTGC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard genetic counseling (SGC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic counseling participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test result acceptors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cancer history
Number of subjects: 0

Group type: COMPARATOR
Intervention: BRCA1/2 prior probability
Number of subjects: 0
Study: 17699970

Group type: EXPERIMENTAL
Intervention: 750 ml spacer with valve
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 165 ml spacer with valve
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 250 ml spacer without valve
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1000 ml indigenously made spacer without valve
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 500 ml indigenously made spacer without valve
Number of subjects: 150
Study: 15601653

Group type: EXPERIMENTAL
Intervention: Intravenous quinine followed by oral Malarone
Number of subjects: 360

Group type: COMPARATOR
Intervention: Intravenous quinine followed by oral quinine
Number of subjects: 360
Study: 12161054

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including didactic training and computerized compliance feedback for diabetes management.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group) during the same period.
Number of subjects: 0
Study: 10214498

Group type: EXPERIMENTAL
Intervention: Cartoon message about safe sex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Written message about safe sex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both messages (cartoon and written)
Number of subjects: 0
Study: 7783024

Group type: EXPERIMENTAL
Intervention: Bair Hugger forced‐warm air warming blanket
Number of subjects: 32

Group type: COMPARATOR
Intervention: Blanketrol water coil‐heated hypothermia blanket
Number of subjects: 32
Study: 2191586

Group type: EXPERIMENTAL
Intervention: Spironolactone + altizide (S/A)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Enalapril (control)
Number of subjects: 186
Study: 6775518

Group type: EXPERIMENTAL
Intervention: High nitrogen (N) intravenous nutritional regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isocaloric regimen containing no amino acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High nitrogen group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (high nitrogen and isocaloric)
Number of subjects: 0